SciBase: Interim report

SciBase: Interim report

PR Newswire

STOCKHOLM, May 13, 2025

STOCKHOLM, May 13, 2025 /PRNewswire/ -- 

January 1 - March 31, 2025

The first quarter in figures 

Important events during the quarter 

Important events after the end of the period 




Apr 1, 2024 - 



Jan 1 - March 31

March 31, 2025

Jan 1 - Dec 31

THE GROUP

2025

2024

Rolling-12

2023

Net sales, SEK ths

8 856

6 057

32 503

29 705

Gross margin, %

70,5 %

69,9 %

71,0 %

71,0 %

Equity/Asset ratio, %

71,6 %

58,2 %

65,5 %

59,4 %

Net indebtness, multiple

0,40

0,72

0,53

0,68

Cash equivalents, SEK ths

34 295

20 272

34 295

11 245

Cashflow from operating activities, SEK ths

-26 001

-13 182

-70 203

-57 383

Earnings per share (before and after dilution), SEK

-0,09

-0,09

-0,35

-0,34

Shareholder's equity per share, SEK

0,14

0,25

0,16

0,21

Average number of shares, 000'*

298 710

119 831

222 713

177 994

Number of shares at closing of period, 000'*

338 296

119 831

338 296

219 538

Share price at end of period, SEK

0,42

0,39

0,42

0,41

Number of sold electrodes, pieces

17 870

13 724

66 356

62 210

Average number of employees

35

26

28

28

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on May 13, 2025.

This interim report report has not been subject to review by the Company's auditors

Contact person:

Michael Colérus, CFO, +46 70 341 34 72

For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: pia.renaudin@scibase.com

Certified Advisor (CA):

Carnegie Investment Bank AB (publ) Phone: +46 (0)73 856 42 65 E-mail: certifiedadviser@carnegie.se

About SciBase 

SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops and commercializes Nevisense, a unique point-of-care platform that combines AI (artificial intelligence) and advanced EIS technology to enhance diagnostic accuracy, ensuring proactive skin health management.

Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs.

Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/interim-report,c4149173

The following files are available for download:

https://mb.cision.com/Main/12371/4149173/3444012.pdf

SciBase Interim report Q1 2025

Cision View original content:https://www.prnewswire.co.uk/news-releases/scibase-interim-report-302453461.html

Voltar noticias em Inglês